345 related articles for article (PubMed ID: 12720270)
1. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
[TBL] [Abstract][Full Text] [Related]
2. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Fröhlich JM
J Magn Reson Imaging; 2004 Mar; 19(3):375-6; author reply 376. PubMed ID: 14994308
[No Abstract] [Full Text] [Related]
3. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C
Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
[TBL] [Abstract][Full Text] [Related]
4. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
[TBL] [Abstract][Full Text] [Related]
5. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
Grazioli L; Morana G; Kirchin MA; Schneider G
Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
[TBL] [Abstract][Full Text] [Related]
6. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
del Frate C; Bazzocchi M; Mortele KJ; Zuiani C; Londero V; Como G; Zanardi R; Ros PR
Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
[TBL] [Abstract][Full Text] [Related]
7. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
[TBL] [Abstract][Full Text] [Related]
10. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
11. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI.
Mortelé KJ; Praet M; Van Vlierberghe H; de Hemptinne B; Zou K; Ros PR
Abdom Imaging; 2002; 27(6):700-7. PubMed ID: 12395259
[TBL] [Abstract][Full Text] [Related]
12. Focal nodular hyperplasia: lesion characteristics on state-of-the-art MRI including dynamic gadolinium-enhanced and superparamagnetic iron-oxide-uptake sequences in a prospective study.
Terkivatan T; van den Bos IC; Hussain SM; Wielopolski PA; de Man RA; IJzermans JN
J Magn Reson Imaging; 2006 Oct; 24(4):864-72. PubMed ID: 16947339
[TBL] [Abstract][Full Text] [Related]
13. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging.
Kim YK; Lee JM; Kim CS; Chung GH; Kim CY; Kim IH
Eur Radiol; 2005 Feb; 15(2):220-8. PubMed ID: 15624108
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
15. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
17. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
[TBL] [Abstract][Full Text] [Related]
18. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
19. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].
Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A
Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542
[TBL] [Abstract][Full Text] [Related]
20. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times.
Kim JH; Kim MJ; Suh SH; Chung JJ; Yoo HS; Lee JT
J Magn Reson Imaging; 2002 May; 15(5):573-83. PubMed ID: 11997899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
